Τίτλος:
Enhancer of Zeste Homologue 2 Expression in Breast Carcinoma Smears in
Relationship with p53, Ki-67 and Other Prognostic Parameters
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: The polycomb group protein enhancer of zeste homologue 2
(EZH 2) has been reported as a marker of aggressive breast cancer. The
aim of this study was to investigate the correlation between the
expression of EZH 2 with p53 and Ki-67 expression and other
clinicopathological parameters in primary breast carcinomas in order to
determine the role of the above marker as a prognosticator of tumor
aggressiveness and patient outcome. Patients and Methods: One hundred
primary operable breast cancer patients were investigated in order to
identify the expression of EZH 2, Ki-67 and p53 in imprint smears
immunocytochemically. The prevalence of expression of these markers was
then correlated with clinicopathological parameters. Follow-up was
available for all patients. Results: EZH 2 was expressed in 64% of the
cases and correlated with higher levels of p53 (relative risk = 3.00, p
< 0.0001) and Ki-67 (relative risk = 3.25, p < 0.0001). Malignant cells
showed immunoreactivity for all markers in the nucleus. Univariate
analysis revealed a strong association between EZH 2 protein expression
and tumor grade and size, lymph node metastasis, and HER-2 and estrogen
and progesterone receptor status. Multivariable statistical analysis
revealed that lymph node metastasis was the main predictor for EZH 2
expression. Decreased patient survival was also significantly associated
with EZH 2 expression (p < 0.0001). Conclusions: EZH 2 expression may be
a marker of poor prognosis in breast carcinoma patients and has been
suggested as a candidate for targeted therapy. Copyright (C) 2011 S.
Karger AG, Basel
Συγγραφείς:
Athanassiadou, Anna Maria
Tsipis, Angelos
Patsouris, Efstratios
and Gonidi, Maria
Nicolopoulou-Stamati, Polyxeni
Chelidonis,
George
Athanassiadou, Pauline
Περιοδικό:
Acta Cytologica
Λέξεις-κλειδιά:
Breast carcinoma; EZH 2; Ki-67; p53
